These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6851402)

  • 1. Hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol.
    Dahlström U; Atterhög JH; Jorfeldt L
    Clin Pharmacol Ther; 1983 Jun; 33(6):701-9. PubMed ID: 6851402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioselectivity of prenalterol and isoproterenol.
    Jennings G; Bobik A; Oddie C; Hargreaves M; Korner P
    Clin Pharmacol Ther; 1983 Dec; 34(6):749-57. PubMed ID: 6641090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.
    Tweddel AC; Murray RG; Pearson D; Martin W; Hutton I
    Br Heart J; 1982 Apr; 47(4):375-80. PubMed ID: 6121566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic and myocardial metabolic effects of the beta-agonist prenalterol in ischemic left ventricular dysfunction.
    Kirlin PC; Walton JA; Brymer JF; Beauman G; Pitt B
    J Cardiovasc Pharmacol; 1984; 6(5):852-8. PubMed ID: 6209491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
    Waagstein F; Estrada-Yamamoto M; Reiz S; Reyes C; Hjalmarson A
    Acta Med Scand Suppl; 1982; 659():221-31. PubMed ID: 6127891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenalterol: a partial beta 1-adrenoceptor agonist or a beta-blocker with intrinsic activity?
    Wirtzfeld A; Klein G; Bibra HV; Sauer E
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):20-7. PubMed ID: 2859252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of long-term beta receptor stimulation with prenalterol on intrinsic heart rate in rats.
    Nylander E; Dahlström U
    Eur J Appl Physiol Occup Physiol; 1984; 53(1):48-52. PubMed ID: 6150847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
    Roubin GS; Choong CY; Devenish-Meares S; Sadick NN; Fletcher PJ; Kelly DT; Harris PJ
    Circulation; 1984 May; 69(5):955-62. PubMed ID: 6142775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.
    Rönn O; Fellenius E; Graffner C; Johnsson G; Lundborg P; Svensson L
    Eur J Clin Pharmacol; 1980 Feb; 17(2):81-6. PubMed ID: 6102914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Echocardiographic measurements of hemodynamic effects and pharmacokinetics of prenalterol (author's transl)].
    Oltmanns D; Wester HA; Stein R
    Z Kardiol; 1981 May; 70(5):394-8. PubMed ID: 6115520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of i.v. prenalterol in patients with severe cardiac failure at rest and during exercise.
    Doering W; Wauer B; Isbary J
    Acta Med Scand Suppl; 1982; 659():307-14. PubMed ID: 6127897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the vasodilator prazosin and the selective beta1 agonist prenalterol on rest and exercise haemodynamics in CHF.
    Hutton I; Tweddel AC; Bastian BC; Murray RG
    Acta Med Scand Suppl; 1981; 652():163-8. PubMed ID: 6120615
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemodynamic effects of atrial pacing and prenalterol infusion in patients taking beta-adrenergic blocking drugs.
    Shiu MF; Ireland MA; Littler WA
    Circulation; 1981 Dec; 64(6):1135-41. PubMed ID: 6117380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of prenalterol in diabetic patients.
    Oltmanns D
    Acta Med Scand Suppl; 1982; 659():147-55. PubMed ID: 6127885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of prenalterol in healthy subjects.
    Johnsson G
    Acta Med Scand Suppl; 1982; 659():109-22. PubMed ID: 6127882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The haemodynamic effects of dopamine and prenalterol in patients after cardiac valve surgery.
    Tydén H; Johansson L; Nyström SO
    Acta Anaesthesiol Scand; 1982 Oct; 26(5):468-73. PubMed ID: 6128857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
    Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
    Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers.
    Svendsen TL; Hartling OJ; Trap-Jensen J
    Eur J Clin Pharmacol; 1980 Oct; 18(3):219-23. PubMed ID: 6108219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure.
    Kupper W; Schütt M; Hamm CW; Kuck KH; Hanrath P; Bleifeld W
    Eur Heart J; 1983 Aug; 4(8):573-83. PubMed ID: 6139281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.